Full-Time

IT Compliance Manager

Posted on 12/20/2024

Penumbra Inc

Penumbra Inc

1,001-5,000 employees

Develops medical devices for vascular conditions

Compensation Overview

$140k - $180kAnnually

Expert

Company Historically Provides H1B Sponsorship

Alameda, CA, USA

Position requires onsite presence in Alameda, CA.

Category
Cybersecurity
IT Project Management
IT & Security
Required Skills
Word/Pages/Docs
Excel/Numbers/Sheets
Requirements
  • Bachelor's degree in computer science or related field with 10+ years of experience, or equivalent combination of education and experience
  • 10+ years’ hands-on experience in developing, implementing, and managing enterprise IT audit, governance, and compliance framework is preferred
  • Ability to develop ITGC framework, implement and manage audit, governance, and compliance across all IT domains i.e., Network, Cloud, IAM, Endpoint, Data, Applications and Operations
  • Self-reliant and motivated, with expert level understanding of IT technology stack across Network, IAM, Endpoint, Data, Applications is required
  • Fully self-reliant, hands-on capability across IT technology stack across Network, Cloud, IAM, Endpoint, Data & Applications
  • Expert level knowledge of audit, governance, and compliance frameworks
  • Expert level knowledge of cybersecurity risk management frameworks
  • Strong knowledge of technology landscape, regulatory/legal requirements, and procedures
  • Highly analytical with strong attention to detail
  • Strong oral, written, and interpersonal communication skills
  • Proficiency with MS Word, Excel, and PowerPoint
  • Excellent organizational skills with ability to prioritize assignments while handling various projects simultaneously
Responsibilities
  • Develop the IT General Controls Framework, implement and manage an effective IT controls audit and compliance program for the enterprise across all domains of IT and manage cybersecurity risk to the business
  • Ability to self-audit with limited assistance from system or service owners across all IT domains i.e., Network, Cloud, IAM, Data, Application, IoT, IT and Security Operations/ Engineering
  • Partner with peer teams and business where necessary
  • Expected to be self-reliant on security audits, reviews, evidence retrieval
  • Engage with 3rd party auditors on testing/walk-throughs and address any security gaps
  • Create and manage effective action plans in response to audit discoveries and compliance violations
  • Partner with system owners on IT services audit outcomes, risk management and compliance reporting
  • Advise management on the company’s compliance with laws and regulations through detailed reports
  • Develop, and up-keep company IT security policies and procedures
  • Regularly audit company procedures, practices, and documents to identify possible weaknesses or risks
  • Ensure stakeholders are educated on the latest regulations and processes
  • Resolve business concerns about regulatory and legal compliance
  • Maintain positive rapport with IT teams, business, and auditors through effective communications
  • Develop, self-audit, manage, and oversee IT Controls across all domains of IT i.e., Network security, Cloud Security, Infrastructure security, End-point security, IAM, Data security, Endpoint security, Application security, IT/ Security operations, ensuring internal and regulatory compliance, working with peer teams to address any gaps and report on compliance
  • Adhere to the Company’s Quality Management System (QMS) as well as domestic and global quality system regulations, standards, and procedures
  • Understand relevant security, privacy and compliance principles and adhere to the regulations, standards, and procedures that are applicable to the Company
  • Ensure other members of the department follow the QMS, regulations, standards, and procedures
  • Perform other work-related duties as assigned

Penumbra Inc. specializes in creating medical devices aimed at treating neurovascular and peripheral vascular conditions. Their products include a variety of devices for neuro interventions, such as the Penumbra System and the Penumbra SMART COIL, which are used to address issues like stroke. For peripheral vascular diseases, they offer the Indigo System and related devices. These products are designed to assist healthcare professionals in hospitals and clinics, primarily in Europe and the Americas. Penumbra differentiates itself from competitors by focusing on specialized solutions for complex medical conditions and maintaining a strong commitment to research and development to enhance their offerings. The company's goal is to provide effective medical devices that improve patient outcomes in the fields of neurology and vascular surgery.

Company Size

1,001-5,000

Company Stage

IPO

Total Funding

$116.7K

Headquarters

Alameda, California

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • Growing demand for minimally invasive procedures boosts Penumbra's neurovascular device market.
  • Technological advancements in catheter-based interventions create innovation opportunities for Penumbra.
  • Expansion of healthcare infrastructure in emerging markets offers global growth potential for Penumbra.

What critics are saying

  • Layoffs in the Immersive Healthcare business may indicate financial or strategic challenges.
  • Retirement of Don Kassing could lead to leadership and strategic guidance gaps.
  • Expansion in Costa Rica may expose Penumbra to operational and supply chain risks.

What makes Penumbra Inc unique

  • Penumbra specializes in neurovascular and peripheral vascular medical devices.
  • The company offers innovative solutions like the Penumbra System and Indigo System.
  • Penumbra's products are used globally, including in Europe, the Americas, and Asia.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Parental Leave

Paid Vacation

Paid Sick Leave

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Neuro News International
Feb 28th, 2025
Penumbra launches Access25 delivery microcatheter designed for brain aneurysm access

Penumbra launches Access25 delivery microcatheter designed for brain aneurysm access.

PR Newswire
Feb 21st, 2025
Penumbra, Inc. Announces Don Kassing Will Retire From Board Of Directors

ALAMEDA, Calif., Feb. 21, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced today that after 17 years of distinguished service, Don Kassing has notified the company that he will retire from the board of directors effective April 1, 2025. Kassing joined Penumbra's Board of Directors in 2008 and has served as Presiding Director since 2015."We are grateful for Don's many contributions to the board over the years, particularly his wisdom and guidance in complex situations and through our phases of growth," said Adam Elsesser, board chair, president and chief executive officer of Penumbra. "We also thank Don for his steadfast leadership and dedication to helping Penumbra advance our mission of helping more and more people over the years."Mr. Kassing is President Emeritus of San Jose State University

Investing.com
Feb 19th, 2025
UBS raises Penumbra stock price target to $320, keeps buy rating

Penumbra plans to expand its manufacturing capacity with a new facility in Costa Rica.

PR Newswire
Feb 18th, 2025
Penumbra, Inc. Reports Fourth Quarter And Full Year 2024 Financial Results

ALAMEDA, Calif., Feb. 18, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2024. Financial Highlights: Adjusted revenue1 of $321.3 million, excluding the $5.8 million impact of the Italian government's payback provision pertaining to prior years, an increase of 12.9% adjusted2 or 13.0% in adjusted constant currency2 compared to the fourth quarter of 2023. Adjusted revenue1 of $1,200.4 million, excluding the $5.8 million impact of the Italian government's payback provision pertaining to prior years, an increase of 13.4% in adjusted2 and adjusted constant currency2 compared to the full year 2023

PR Newswire
Jan 21st, 2025
Penumbra, Inc. Schedules Fourth Quarter And Full Year 2024 Earnings Release And Conference Call For February 18, 2025

ALAMEDA, Calif., Jan. 21, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2024 after market close on Tuesday, February 18, 2025 at 4:30 PM Eastern Time. A press release with fourth quarter and full year 2024 financial results will be issued after market close that day.Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 5872954), or the webcast can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at www.penumbrainc.com. The webcast will be available on the company's website for at least two weeks following the completion of the call.About PenumbraPenumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity

INACTIVE